[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527353":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":22,"locations":30,"responsibleParty":53,"collaborators":10,"id":55,"slug":10,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants receiving mavacamten for oHCM",null,[12],"Drug: Mavacamten",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Mavacamten","According to approved product label",[9],[20],{"name":5,"affiliation":5,"role":21},"STUDY_DIRECTOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[31,43],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Local Institution - 0001","TERMINATED","Seoul","06234","South Korea",{"type":38,"coordinates":39},"Point",[40,41],126.9784,37.566,{"lat":41,"lon":40},{"facility":44,"status":45,"city":34,"state":10,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":46,"geoPoint":48,"contacts":49},"Novotech Laboratory Korea Co., Ltd.","RECRUITING",{"type":38,"coordinates":47},[40,41],{"lat":41,"lon":40},[50],{"name":51,"role":25,"phone":52,"phoneExt":10,"email":10},"South Korea Generic Country, Site 0002","0000000000",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100527353",false,"NCT06146660","A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy","CAMZYOS® (Mavacamten) Post-Marketing Surveillance in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)","Inclusion Criteria:\n\n* Adult participants 19 years of age or older\n* Participants who receive mavacamten according to the approved product label\n* Participants who sign the informed consent form\n\nExclusion Criteria:\n\n* Participants who are prescribed mavacamten for therapeutic indications not approved in Korea\n* Participants for whom mavacamten is contraindicated as clarified in Korean prescribing information approved by the Ministry of Food and Drug Safety","ALL","19 Years",{"count":64,"type":65},600,"ESTIMATED","OBSERVATIONAL","The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.",[69],"Obstructive Hypertrophic Cardiomyopathy","2024-11-05",{"date":72,"type":73},"2024-11-06","ACTUAL",{"date":75,"type":73},"2024-07-24",{"date":77,"type":65},"2026-11-30",{"name":5,"class":6},2]